Wall Street Zen Upgrades NeuroOne Medical Technologies (NASDAQ:NMTC) to Sell

NeuroOne Medical Technologies (NASDAQ:NMTC) was upgraded by Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Zacks Research raised NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NeuroOne Medical Technologies has an average rating of “Moderate Buy” and an average target price of $2.23.

NeuroOne Medical Technologies Price Performance

Shares of NeuroOne Medical Technologies stock opened at $0.68 on Friday. NeuroOne Medical Technologies has a 1-year low of $0.40 and a 1-year high of $1.18. The company’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $0.80. The stock has a market capitalization of $34.36 million, a PE ratio of -4.00 and a beta of 0.70.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. The firm had revenue of $2.89 million during the quarter, compared to analyst estimates of $2.47 million. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NMTC. Goldman Sachs Group Inc. bought a new stake in shares of NeuroOne Medical Technologies during the first quarter valued at approximately $84,000. Warberg Asset Management LLC purchased a new position in NeuroOne Medical Technologies during the second quarter valued at $27,000. XTX Topco Ltd bought a new stake in NeuroOne Medical Technologies in the 2nd quarter valued at $51,000. Sio Capital Management LLC bought a new stake in NeuroOne Medical Technologies in the 2nd quarter valued at $2,390,000. Finally, Focus Financial Network Inc. purchased a new stake in NeuroOne Medical Technologies in the 3rd quarter worth $31,000. 16.07% of the stock is currently owned by institutional investors.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.